PolyPid Ltd. director awarded options for 9,132 shares

PolyPid Ltd. director Barenholz Yechezkel reported a grant of stock options covering 9,132 Ordinary Shares at an exercise price of 4.46 per share.

Accepted by SEC EDGAR 07/17/2026 - 04:03 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PolyPid Ltd. director Barenholz Yechezkel reported a grant of stock options covering 9,132 Ordinary Shares at an exercise price of 4.46 per share. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030 and expire on 2036-07-15, leaving him holding 9,132 options directly.

Insider Trade Summary

Grant/Award: 9,132 shares

Grant/Award 1 txn

Insider Barenholz Yechezkel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy) F1	9,132	$4.46	$41K

Holdings After Transaction: Stock option (right to buy) — 9,132 contracts (Direct)

Holdings Before and After: Stock option (right to buy), 0 to 9,132 contracts (Direct)

Footnotes (1)

1. F1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.

Key Figures

Stock options granted: 9,132 shares Exercise price: 4.46 per share Underlying Ordinary Shares: 9,132 shares +3 more

6 metrics

Stock options granted 9,132 shares Grant of stock options to director on 2026-07-15

Exercise price 4.46 per share Conversion or exercise price of the options

Underlying Ordinary Shares 9,132 shares Number of Ordinary Shares underlying the options

Expiration date 2036-07-15 Expiration date of the granted stock options

Vesting period July 15, 2026 to April 15, 2030 Options vest on a quarterly basis over this period

Options held after grant 9,132 stock options Total derivative securities held directly following the transaction

Key Terms

Stock option (right to buy), Ordinary Shares, vest on a quarterly basis

3 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

Ordinary Shares financial

"underlying_security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vest on a quarterly basis financial

"The options vest on a quarterly basis beginning July 15, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did PolyPid (PYPD) director Barenholz Yechezkel report on this Form 4?

Barenholz Yechezkel reported receiving a grant of stock options for 9,132 Ordinary Shares of PolyPid Ltd. at an exercise price of 4.46 per share. This award increases his directly held option position to 9,132 derivative securities linked to PolyPid Ordinary Shares.

How many PolyPid (PYPD) shares are covered by the new stock options?

The new award covers 9,132 underlying Ordinary Shares of PolyPid Ltd. Each option represents the right to buy one Ordinary Share, so the grant gives the director potential future ownership of up to 9,132 shares if all options are fully exercised.

What is the exercise price and expiration date of the PolyPid (PYPD) options?

The options have an exercise price of 4.46 per share and an expiration date of 2036-07-15. This means the director may exercise the options at 4.46 per share any time after vesting and before they expire in 2036, subject to plan terms.

When do the PolyPid (PYPD) options begin vesting and when will they be fully vested?

The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030. Vesting in quarterly installments spreads the director’s ability to exercise the award over roughly three years and nine months, aligning option availability with continued service over that period.

Are the reported PolyPid (PYPD) option grants made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked as an affirmative 10b5-1 plan. This suggests the reported option grant is not designated as made pursuant to a pre-arranged Rule 10b5-1 trading arrangement under the form’s specific checkbox disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barenholz Yechezkel

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET ISRAEL

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.46	07/15/2026		A		9,132		10/15/2026(1)	07/15/2036	Ordinary Shares	9,132	$4.46	9,132	D

Explanation of Responses:

1. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030.

	/s/ Barenholz Yechezkel	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)